PJ27 

PJ27 is a dual PD-1/PD-L1/JAK1 inhibitor, with an IC₅₀ of 414 nM against PD-1/PD-L1, an IC₅₀ of 786 nM against JAK1, a K_a of 294 nM for human PD-1/PD-L1, and a K_a of 473 nM for murine PD-1/PD-L1. PJ27 promotes the infiltration of CD3⁺CD8⁺ and CD3⁺CD4⁺ cells into the tumor microenvironment and exerts a significant immune activation effect. PJ27 inhibits tumor growth in a dose-dependent manner in the LLC lung cancer mouse model. PJ27 is applicable to relevant research on lung cancer^[1].

PJ27 (0.125-2 μM; 48 h) enhances Jurkat T cell-mediated killing of PD-L1-expressing A549 cells, with significant A549 viability reduction at 2 μM in co-culture^[1].
PJ27 binds to human and murine PD-L1 with comparable affinity, with K_d values of 294 nM and 473 nM respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PJ27 (25-50 mg/kg; i.p.; daily; 11 days) potently and dose-dependently inhibits LLC lung tumor growth in male C57BL/6J mice, achieving a 56% tumor growth inhibition rate at 50 mg/kg, while enhancing antitumor T cell infiltration and demonstrating no obvious toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

640.78

C₃₈H₄₀N₈O₂

CC1=C(C2=NC(OC)=C(CNC3CCN(C(CCCN4C=C(C5=NC=NC6=C5C=CN6)C=N4)=O)CC3)C=C2)C=CC=C1C7=CC=CC=C7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang Z, et al. Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity. Eur J Med Chem. 2026;306:118605.  [Content Brief]